【摘要】 目的:比较瑞舒伐他汀与阿托伐他汀治疗早发冠心病急性心肌梗死患者的效果。方法:回顾性分析2017年1月至2018年3月佳木斯大学附属第一医院收治的100例早发冠心病急性心肌梗死患者的临床资料,依据治疗方法将其分为对照组与观察组各50例,观察组应用瑞舒伐他汀治疗,对照组应用阿托伐他汀治疗,比较两组治疗效果、治疗前后血脂[总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)]水平与内皮舒张功能(FMD)、左室射血分数(LVEF)及超敏C反应蛋白(hs-CRP)水平,并在治疗6个月后随访,比较预后情况。结果:两组治疗有效率比较,差异无统计学意义(P>0.05);治疗后观察组TC、LDL-C、hs-CRP水平明显优于对照组,差异均有统计学意义(P<0.05);两组不良反应发生率及死亡率比较差异无统计学意义(P>0.05)。结论:阿托伐他汀与瑞舒伐他汀治疗早发冠心病急性心肌梗死患者疗效与安全性相当,但瑞舒伐他汀调节患者血脂水平,改善炎症反应的效果更佳。更多还原

【Abstract】 Objective: To compare effects of Rosuvastatin and Atorvastatin in treatment of patients with premature coronary heart disease and acute myocardial infarction. Methods: The clinical data of 100 patients with premature coronary heart disease and acute myocardial infarction admitted to the first affiliated hospital of Jiamusi university from January 2017 to March 2018 were retrospectively analyzed. According to the treatment method, they were divided into control group and observation group with 50 cases in each. The observation group was treated with Rosuvastatin, while the control group was treated with Atorvastatin. The treatment effects, blood lipid levels [total cholesterol(TC), triacylglycerol(TG), high-density lipoprotein cholesterol(HDL-C), low-density lipoprotein cholesterol(LDL-C)], endothelial diastolic function(FMD), left ventricular ejection fraction(LVEF), and high-sensitivity C-reactive protein level(hs-CRP) before and after the treatment were compared between the two groups. They were followed-up for 6 months, and the prognosis was compared. Results: There was no significant difference in the treatment effective rate between the two groups(P>0.05). After the treatment, the levels of TC, LDL-C, and hs-CRP in the observation group were significantly better than those in the control group, and the differences were statistically significant(P<0.05). There were no significant differences in the levels of hs-CRP, FMD, and LVEF between the two groups before the treatment(P>0.05). However, after the treatment, the hs-CRP level in the observation group was significantly lower than that in the control group, and the difference was statistically significant(P<0.05). Further, there were no significant differences in the incidence of adverse reactions and mortality between the two groups(P>0.05). Conclusions: Atorvastatin and Rosuvastatin are effective and safe in the treatment of the patients with premature coronary heart disease and acute myocardial infarction, but Rosuvastatin is more effective in regulating the blood lipid levels and improving the inflammatory response.更多还原